The Safety/Efficacy of hUC Mesenchymal Stem Cells(19#iSCLife®-OA) Therapy for Patients With Osteoarthritis

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
AgeUp to 70
SponsorSclnow Biotechnology Co., Ltd.

About this trial

The purpose of this study is verify the efficacy and safety of Human Umbilical Cord Mesenchymal Stem Cells (UC-MSC) therapy for patients with Osteoarthritis, and in addition, provide basis for exploring the treatment regimen of UC-MSC therapy in different degree of cartilage defect disease

Eligibility criteria

Qualifiers

Diagnosis of Knee Osteoarthritis by Kellgren and Lawrence Grading Scale, classified with Grade 2-3

Confirm with cartilage injury,articular cartilage part or full-thickness injury, by MR (Magnetic Resonance)

Age <70, no serious organ dysfunction

Over 2 years knee pain or no very effective with conservative treatments

Disqualifiers

Refuse to sign the consent form, or cannot keep follow-up visit

Age >70; Age <70, but with multiple organ failure

Unstable vital signs (breath, blood pressure, pulse)

Combined with knee ligament (anterior and the posterior cruciate ligament, medial and lateral collateral ligament) rupture, laxity, etc.

Trial design

Treatments tested in this trial

  • Low dose mesenchymal stem cells
  • High dose mesenchymal stem cells
  • Intraarticular injection

Treatment groups

60 Participants
are divided into 3 treatment groups

Sponsors and collaborators